Luke L Wang1, Kirobel Begashaw1, Melanie Evans2, Arul Earnest2, Sue M Evans2, Jeremy L Millar3,4, Declan G Murphy5,6, Daniel Moon1,4,5. 1. Australian Urology Associates, Melbourne, Victoria, Australia. 2. School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 3. Radiation Oncology, Alfred Health, Melbourne, Victoria, Australia. 4. Department of Surgery, Central Clinical School, Monash University, Melbourne, Victoria, Australia. 5. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 6. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: To update patterns of care for men diagnosed with prostate cancer in Victoria, Australia between 2008 and 2015. METHODS: From August 2008 to December 2015, 14 025 men diagnosed with prostate cancer were included. These data were obtained from the Prostate Cancer Outcome Registry - Victoria (PCOR-Vic). Frequencies were used to describe hospital and patient characteristics and treatment types. Comparisons were made between previous period of analysis (2008-2011) to the most recent period (2011-2015). Survival analysis using a stepwise Cox proportional hazards regression model was performed. RESULTS: Mean age of diagnosis was 66.5 years and 44% of patients were diagnosed with Gleason 7 prostate cancer. Majority of notifications (63.6%) were received from a private institution and 70.2% of patients were diagnosed at a metropolitan institution. Most patients (95.3%) were diagnosed with clinically localized disease. Within 12 months of diagnosis, 55.9% of patients with low-risk disease received no active treatment. Radical prostatectomy was the most common primary treatment with curative intent (47%). When comparing of patterns of care between 2008-2011 and 2011-2015, the proportion of patients diagnosed with Gleason 9-10 disease increased, as has the proportion of patients diagnosed with metastatic disease. CONCLUSION: With the PCOR-Vic, we were able to identify that increasing number of patients were diagnosed with high-risk and metastatic disease. There has been an overall decrease in radical treatment rates, likely due to active surveillance playing a significant role especially in patients with low-risk prostate cancer.
BACKGROUND: To update patterns of care for men diagnosed with prostate cancer in Victoria, Australia between 2008 and 2015. METHODS: From August 2008 to December 2015, 14 025 men diagnosed with prostate cancer were included. These data were obtained from the Prostate Cancer Outcome Registry - Victoria (PCOR-Vic). Frequencies were used to describe hospital and patient characteristics and treatment types. Comparisons were made between previous period of analysis (2008-2011) to the most recent period (2011-2015). Survival analysis using a stepwise Cox proportional hazards regression model was performed. RESULTS: Mean age of diagnosis was 66.5 years and 44% of patients were diagnosed with Gleason 7 prostate cancer. Majority of notifications (63.6%) were received from a private institution and 70.2% of patients were diagnosed at a metropolitan institution. Most patients (95.3%) were diagnosed with clinically localized disease. Within 12 months of diagnosis, 55.9% of patients with low-risk disease received no active treatment. Radical prostatectomy was the most common primary treatment with curative intent (47%). When comparing of patterns of care between 2008-2011 and 2011-2015, the proportion of patients diagnosed with Gleason 9-10 disease increased, as has the proportion of patients diagnosed with metastatic disease. CONCLUSION: With the PCOR-Vic, we were able to identify that increasing number of patients were diagnosed with high-risk and metastatic disease. There has been an overall decrease in radical treatment rates, likely due to active surveillance playing a significant role especially in patients with low-risk prostate cancer.
Authors: Penelope Schofield; Karla Gough; Amelia Hyatt; Alan White; Mark Frydenberg; Suzanne Chambers; Louisa G Gordon; Robert Gardiner; Declan G Murphy; Lawrence Cavedon; Natalie Richards; Barbara Murphy; Stephen Quinn; Ilona Juraskova Journal: Trials Date: 2021-01-11 Impact factor: 2.279
Authors: Michael Rechtman; Andrew Forbes; Jeremy L Millar; Melanie Evans; Lachlan Dodds; Declan G Murphy; Sue M Evans Journal: BMC Urol Date: 2022-02-07 Impact factor: 2.264
Authors: Thomas Eade; George Hruby; Jeremy Booth; Regina Bromley; Lesley Guo; Andrew O'Toole; Andrew Le; Kenny Wu; May Whitaker; Krishan Rasiah; Venu Chalasani; Justin Vass; Carolyn Kwong; John Atyeo; Andrew Kneebone Journal: Adv Radiat Oncol Date: 2019-04-11